Products
Miromavimab Biosimilar Mouse Monoclonal Antibody (Rabies Virus ERA G Epitope II) for Research
Cat No.: GMP-Bios-ab-348
Pre-Made Miromavimab biosimilar, Whole mAb (Mouse): Anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-II therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-348-1mg | 1mg | 3090 |
| GMP-Bios-ab-348-10mg | 10mg | |
| GMP-Bios-ab-348-100mg | 100mg | |
| GMP-Bios-ab-348-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Miromavimab biosimilar, Whole mAb (Mouse): Anti-Rabies Virus Strain ERA GP Ectodomain Epitope G-II therapeutic antibody |
| INN Name | Miromavimab |
| Target | Rabies Virus Strain ERA GP Ectodomain Epitope G-II |
| Format | Whole mAb (Mouse) |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Candila Healthcare |
| Conditions Approved | Rabies |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | na |
